Coexistence of systemic sclerosis, scleroderma-like syndromes and neoplastic diseases

Polskie Archiwum Medycyny Wewnetrznej

Volumn 118, Issue 3, 2008, Pages 119-126

  Ciołkiewicz, Mariusz ^a   Domysławska, Izabela ^a   Ciołkiewicz, Agata ^b   Klimiuk, Piotr Adrian ^a   Kuryliszyn Moskal, Anna ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Department of Internal Medicine and Cardiology   (Poland)

Author keywords

Neoplasm; Scleroderma like syndrome; Systemic sclerosis

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CHEMICAL COMPOUND; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; DOCETAXEL; DRUG METABOLITE; GEMCITABINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MONOCLONAL ANTIBODY; ORGANIC SOLVENT; PACLITAXEL; TUMOR MARKER; UFT;

BLADDER CARCINOMA; BREAST CANCER; CANCER RISK; CARCINOGENESIS; CARCINOGENICITY; CLINICAL FEATURE; COMORBIDITY; DERMATOMYOSITIS; DISEASE ASSOCIATION; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; FAMILY HISTORY; GENETIC DISORDER; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSTIMULATION; LUNG CANCER; LUNG FIBROSIS; MALIGNANT TRANSFORMATION; NEOPLASM; RADIATION; RAYNAUD PHENOMENON; RETICULOENDOTHELIAL NEOPLASM; REVIEW; RHEUMATIC DISEASE; RHEUMATIC PARANEOPLASTIC SYNDROME; RHEUMATOID ARTHRITIS; RISK FACTOR; SCLERODERMA; SCLERODERMA LIKE SYNDROME; SIDE EFFECT; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TUMOR CELL; VIRUS;

EID: 41749096342     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Naschitz JE, Rosner I, Rozenbaum M, et al. Rheumatic Syndromes: Clues to Occult Neoplasia. Semin Arthritis Rheum. 1999; 29: 43-55.
2. Rosenthal AK, McLaughlin JK, Linet MS, et al. Scleroderma and malignancy: an epidemiologic study. Ann Rheum Dis. 1993; 52: 531-533.
3. Rosenthal A, McLaughlin JK, Gridley G, Nyren O. Incidence of cancer among patients with systemic sclerosis. Cancer. 1995; 76: 910-914.
4. Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993; 20: 1335-1339.
5. Banaś M, Kotulska A, Kucharz EJ, et al. Zmiany w narza̧dzie ruchu jako pierwszy objaw ostrej białaczki limfoblastycznej: opis przypadku. Pol Arch Med Wewn. 2005; 114: 681-683.
6. Hrycek A, Olszanecka-Glinianowicz M, Życiński P. Dyskusja zwia̧zana z trudnościami diagnostycznymi w przypadku chorego z toczniem rumieniowatym układowym i nastȩpczo rozpoznanym rakiem płuc poprzedzonych zawodowa̧ ekspozycja̧ na pył krzemowy. Pol Arch Med. Wewn. 2007; 117: 109-112.
7. Caldwell DS, McCallum RM. Rheumatologic manifestations of cancer. Med Clin North Am. 1986; 70: 385-417.
8. Butler RC, Thompson JM, Keat ACS. Paraneoplastic rheumatic disorders: a review. J R Soc Med. 1987; 80: 168-172.
9. Brooks PM. Rheumatic manifestations of neoplasia. Curr Opin Rheum. 1992; 4: 90-93.
10. Mertz LE, Corm DL. Vasculitis associated with malignancy. Curr Opin Rheum. 1992; 4: 39-46.
11. Sela O, Shoenfeld Y. Cancer in autoimmune diseases. Semin Arthritis Rheum. 1988; 18: 77-78.
12. Sanchez-Guerrero J, Gutieńez-Urena S, V Daller A, et al. Vasculitis as a paraneoplastic syndrome: report of 11 cases and review of the literature. J Rheumatol. 1990; 17: 1458-1462.
13. Medsger TA, Dixon JA, Garwood VE. Palmar fasciitis and polyarthritis associated with ovarian carcinoma. Ann Intern Med. 1982; 96: 424-431.
14. Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol. 1994; 21: 1855-1859.
15. Naschitz JE, Yeshurun O, Rusher I. Rheumatic manifestations of occult cancer. Cancer. 1995; 75: 2954-2958.
16. Rozenbanm M, Naschitz JE, Rosner I, et al. Paraneoplastic lenkocytoclastic vasculitis: remission of protracted lenkocytoclastic vasculitis after resection of a pulmonary adenocarcinoma. J Clin Rheumatol. 1996; 2: 99-102.
17. Hall TC. Paraneoplastic syndromes: mechanisms. Semin Oncol. 1997; 24: 269-276.
18. Szekanecz E, Andras E, Sandor Z, et al. Malignancies and soluble tumor antigens in rheumatic diseases. Autoimmun Rev. 2006; 6: 42-47.
19. Nathanson L, Hall TC. Introduction: paraneoplastic syndromes. Semin Oncol. 1997; 24: 265-268.
20. Naschitz JE, Yeshurun D, Eldar S, et al. Diagnosis of cancer-associated vascular disorders. Cancer. 1996; 77: 1759-1767.
21. D'Cruz D. Autoimmune diseases associated with drugs, chemicals and enviromental factors. Toxicol Lett. 2000; 112-113: 421-432.
22. Hassett G, Harnett P, Manoilos G. Scleroderma in associastion with the use of docetaxel (taxotere for breast cancer). Clin Exp Rheumatol. 2001; 19: 197-200.
23. De Angelis R, Bugatti L, Cerioni A, et al. Diffuse scleroderma occuring after the use of paclitaxel for ovarian cancer. Clin Rheumatol. 2003; 22: 49-52.
24. Kerr LD, Spiera H. Scleroderma in association with the use of bloemycin; a report of 3 cases. J Rheumatol. 1992; 19: 294-296.
25. Karim E, Vaux E, Davis DR, et al. Renal failure due to scleroderma with thrombothic microangiopathy developing in a woman treated with carboplatin for ovarian cancer. Clin Nephrol. 2002; 58: 384-388.
26. Bessis D. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004; 51: S73-76.
27. Davis DA, Cohen PR, McNeese MD, et al. Localized scleroderma in breast cancer patients treated with supervoltage external beam radiation: Radiation port scleroderma. J Am Acad Dermatol. 1996; 35: 923-927.
28. Shokri IV, Mageed RA, Maziak BR, et al. Lymphoproliferation in primary Sjogren's syndrome: evidence of selective expansion of a B-cell sunset characterized by the expression of cross-reactive idiotypes. Arthritis Rheum. 1993; 36: 1128-1136.
29. Kassan SS, Thomas T, Montsupoulos H, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978; 89: 888-892.
30. Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum. 1997; 40: 1580-1586.
31. Tennis E, Andrews E, Bombardier C, et al. Record linkage to conduct an epidemiologic study on the association of rheumatoid arthritis and lymphoma in the province of Saskachewan, Canada. J Clin Epidemiol. 1993; 46: 685-695.
32. Airio A, Pukkala E, Isomaki H. Elevated cancer incidence with dermatomyositis: a population-based study. J Rheumatol. 1995; 22: 1300-1303.
33. Abu-Shakra M, Gladman DD, Urowitz MB. Malignancy in systemic lupus erythematosus. Arthritis Rheum. 1996; 39: 1050-1054.
34. Abu-Shakra M, Guillemin F, Lee P. Cancer in systemic sclerosis. Arthritis Rheum. 1993; 36: 460-464.
35. Kamel OW, van de Rijn M, Weiss LM, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med. 1993; 328: 1317-1321.
36. Radis CD, Kahl LE, Baker GK, et al. Effects of cyclophosphamide on the development of malignancy and long-term survival of patients with rheumatoid arthritis: a 20-year follow-up study. Arthritis Rheum. 1995; 38: 1120-1127.
37. Arenallo E, Krupp R. Malignancies in rheumatoid arthritis patients treated with cyclosporin. A. Br J Rheumatol. 1993; 32: 72-75.
38. Tamby MC. New insights into the pathogenesis of systemic sclerosis. Autoimmun Rev. 2003; 2: 152-157.
39. Lee P, Alderdice C, Wilkinson S, et al. Malignancy in progressive systemic sclerosis - association with breast carcinoma. J Rheumatol. 1983; 10: 665-666.
40. Kong FM, Anscher MS, Murase T, et al. Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg. 1995; 222: 155-162.
41. Silver I, Heyes MP, Maize JC, et al. Scleroderma, fascitis and eosinophila associated with the ingestion of tryptophan. N Engl J Med. 1990; 322: 874-881.
42. Brinton LA, Buckley LM, Dvorkina O, et al. Risk of connective tissue disorders among breast implant patients. Am J Epidemiol. 2004; 160: 619-627.
43. Levine J, Ilowite NT. Sclerodermalike esophageal disease in children breast-fed by mothers with silicone breast implants. JAMA. 1994; 271: 213-216.
44. Zatuchni J, Campbell WJ, Zarafonetis CJD. Pulmonary fibrosis and terminal bronchiolar carcinoma in scleroderma. Cancer. 1953; 6: 1147-1158.
45. Kyndt X, Hebbar M, Queyrel V, et al. Sclerodermic systemique et cancer. Recherche de facteur predictifs de cancer chez 123 patients sclerodermiques. Rev Med Interne 1997; 18: 528-532.
46. Pearson JE, Silman AJ. Risk of cancer in patients with scleroderma. Ann Rheum Dis. 2003; 62: 697-700.
47. Benedek TG. Neoplastic associations of rheumatic diseases and rheumatic manifestations of cancer. Clin Geriatr Med. 1988; 4: 333-355.
48. Peters-Golden M. Incidence of lung cancer in systemic sclerosis. J Rheumatol. 1985; 12: 1136-1139.
49. Winkelmann RK. Lung cancer ad scleroderma. Arch Dermatol Res. 1988; 280 (Suppl): S15-S18.
50. Bielefeld P. Sclerodermie systemique et cancers: 21 observation et revue da la literature. Rev Med Interne. 1996; 17: 810-813.
51. Hill CL, Nguyen AM, Roder D, et al. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis. 2003; 62: 728-731.
52. Higuchi M. Anticentromere antibody as a risk factor for cancer in patients with systemic sclerosis. Clin Rheumatol. 2000; 19: 123-126.
53. Derk CT. Autoantibodies in patients with systemic sclerosis and cancer: a case-control study. J Rheumatol. 2003; 30: 1994-1996.
54. Hebbar M, Lassalle P, Janin A, et al. E-selectin expression in salivary endothelial cells and sera of patients with systemic sclerosis. Role of resident mast cell-derived tumor necrosis factor alpha. Arthritis Rheum. 1995; 38: 406-412.
55. Koch AE, Halloran MM, Haskell CJ, et al. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature. 1995; 376: 517-519.
56. Querfeld C, Sollberg S, Huerkamp C, et al. Pseudoscleroderma associated with lung cancer: correlation of collage type I and connective tissue growth factor gene expression. Br J Dermatol. 2000; 142: 1228-1233.
57. Carsons S. The association of malignancy with rheumatic and connective tissue diseases. Sem Onc. 1997; 24: 360-372.
58. Forbes AM, Woodrow JC, Verbov JL, et al. Carcinoma of the breast and scleroderma: four further cases and a literature review. Br J Rheumatol. 1989; 28: 65-69.
59. Pineda V, Salvador R, Soriano J. Bilateral breast cancer associated with diffuse scleroderma. Breast. 2003: 12: 217-219.
60. Gruber BL, Miller F, Kaufman LD. Simultaneous onset of systemic sclerosis (scleroderma) and lung cancer: a case report and histologic analysis of fibrogenic peptides. Am J Med. 1992; 92:705-708.
61. Botsios C, Ostuni P, Cozzi F, et al. Systemic sclerosis in a patient with recent nasopharyngeal carcinoma: an unusual combination. Joint Bone Spine. 2003; 70: 396-400.
62. Schwartz RA, Burgess GH, Fox MD: Sclerodermoid changes in a patient with metastatic malignant melanoma. J Dermatol Surg Oncol. 1980; 6:112-114.
63. Cleenewerk N, Leone J, Demage L, et al. Sclerodermie systemique et sarcome du mesentere. Rev Med Interne. 1997; 18: 676-678.
64. Soubrier MJ, Dubost JJ, Sauvezie BJ. POEMS syndrome: a study of 25 cases and a review of the literature. French Study Group on POEMS Syndrome. Am J Med. 1994; 97: 543-553.
65. Khraishi M, Howard B, Little H. A patient with Werner's syndrome and osteosarcoma presenting as scleroderma. J Rheumatol. 1992; 19: 810-813.
66. Duvic M. Lemak NA. Werner's syndrome. Dermatol Clin. 1995; 13: 163-168.
67. Goto M, Okawa-Takatsuji M, Aotsuka S, et al. Significant elevation of IgG anti-WRN (RecQ3 RNA/DNA helicase) antibody in systemic sclerosis. Mod Rheumatol. 2006; 16: 229-234.
68. Roberts-Thomson PJ, Male DA, Walker JG, et al. Genomic instability in scleroderma. Asian Pac J Allergy Immunol. 2004; 22: 153-158.
69. Sakkas LI. Cancer in families with systemic sclerosis. Am J Med Sci. 1995; 310: 223-225.
70. DeCross AJ, Sahasrabudhe DM. Paraneoplastic Raynand's phenomenon. Am J Med 1992; 92: 570-572.
71. Naschitz JE, Yeshurun D, Abrahamson J. Arterial occlusive disease in occult cancer. Am Heart J. 1992; 124: 738-745.
72. Hladunewich M, Sawka C, Fam AG, et al. Raynaud's phenomenon and digital gangrene as a consequence of treatment for Kaposi's sarcoma. J Rheumatol. 1997; 24: 2371-2375.
73. Maravic M, Cojean-Zelek I, Chazerain P, et al. Manifestations rhumatologiques des anticancéreux. Rev Rhum [Éd Fr]. 2002; 69: 424-433.
74. Kono T, Ishii M, Negoro N, et al. Scleroderma-like reaction induced by uracil-tegafur (UFT), a second-generation anticancer agent. J Am Acad Dermatol. 2000; 42: 519-520.
75. Yamamoto T. Animal model of sclerotic skin induced by bleomycin: a clue to the pathogenesis of and therapy for scleroderma? Clin Immunol. 2002; 102: 209-216.
76. Yamamoto T: Increased expression of p53 and p21 (Waf1/Cip1) in the lesional skin of bleomycin-induced scleroderma. Arch Dermatol Res. 2005; 296: 509-513.
77. Reddy SM, Pui JC, Gold LI, et al. Postirradiation morphea and subcutaneous polyarteritis nodosa: Case report and literature review. Semin Arthritis Rheum. 2005; 34: 728-734.
78. Vinzio S, Lioure B, Grunenberger F, et al. Auto-immune-like disease post-bone marrow transplantation. Rev Med Interne. 2004; 25: 514-523.
79. Artlett CM. Microchimerism and scleroderma: an update. Curr Rheumatol Rep. 2003; 5: 154-159.
80. Niemczyk M, Foroncewicz B, Mucha K. Rola TGF beta. Pol Arch Med Wew. 2005; 113: 401-414.
81. Fam AG. Paraneoplastic rheumatic syndromes. Bailliere Best Pract Res Clin Rheumatol. 2000; 14: 515-533.